Origin of the vasculature supporting growth of primary patient tumor xenografts

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Hylander, Bonnie L ^a   Punt, Natalie ^a   Tang, Haikuo ^a,b   Hillman, Joanna ^a   Vaughan, Mary ^a   Bshara, Wiam ^a   Pitoniak, Rose ^a   Repasky, Elizabeth A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine   (China)

Author keywords

Patient tumor xenograft; Primary xenograft; Vascularization

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD VESSEL; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; COLON TUMOR; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; SOLID TUMOR; STROMA; TISSUE PREPARATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84876967149     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-110     Document Type: Article

References (32)

1. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14(20):6456-6468. 10.1158/1078-0432.CCR-08-0138, 18927285.
2. Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 1991, 88(20):9345-9349. 10.1073/pnas.88.20.9345, 52711, 1924398.
3. Grisanzio C, Seeley A, Chang M, Collins M, Di Napoli A, Cheng SC, Percy A, Beroukhim R, Signoretti S. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol 2011, 225(2):212-221. 10.1002/path.2929, 21710693.
4. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005, 3(1):22. 10.1186/1479-5876-3-22, 1156958, 15943879.
5. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012, 18(19):5314-5328. 10.1158/1078-0432.CCR-12-0372, 22825584.
6. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009, 4(11):1670-1680. 10.1038/nprot.2009.171, 19876027.
7. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002, 62(20):5800-5806.
8. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006, 12(15):4652-4661. 10.1158/1078-0432.CCR-06-0113, 16899615.
9. Seshadri M, Merzianu M, Tang H, Rigual NR, Sullivan M, Loree TR, Popat SR, Repasky EA, Hylander BL. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther 2009, 8(23):2275-2283. 2906774, 19829072.
10. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10(8):1311-1316. 10.1158/1535-7163.MCT-11-0233, 21673092.
11. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012, 10(1):125. 10.1186/1479-5876-10-125, 3439334, 22709571.
12. Uronis JM, Osada T, McCall S, Yang XY, Mantyh C, Morse MA, Lyerly HK, Clary BM, Hsu DS. Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS One 2012, 7(6):e38422. 10.1371/journal.pone.0038422, 3366969, 22675560.
13. Lin MT, Tseng LH, Kamiyama H, Kamiyama M, Lim P, Hidalgo M, Wheelan S, Eshleman J. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Biotechniques 2010, 48(3):211-218. 10.2144/000113363, 3065779, 20359302.
14. Lehr HA, Skelly M, Buhler K, Anderson B, Delisser HM, Gown AM. Microvascular endothelium of human tumor xenografts expresses mouse (= host) CD31. Int J Microcirc Clin Exp 1997, 17(3):138-142. 10.1159/000179221, 9272464.
15. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66(7):3351-3354. discussion 3354, 10.1158/0008-5472.CAN-05-3627, 16585151.
16. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000, 97(26):14608-14613. 10.1073/pnas.97.26.14608, 18966, 11121063.
17. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000, 156(2):361-381. 10.1016/S0002-9440(10)64739-6, 1850026, 10666364.
18. Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, Civenni G, Sommer L, Moch H, Dummer R. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012, 7(3):e33571. 10.1371/journal.pone.0033571, 3307737, 22442699.
19. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011, 108(11):4274-4280. 10.1073/pnas.1016030108, 3060261, 21262804.
20. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9(6):338-350. 10.1038/nrclinonc.2012.61, 22508028.
21. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS, Repasky EA. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 1999, 72(2):161-170. 10.1006/gyno.1998.5238, 10021295.
22. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK, Smith GJ. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 2004, 64(5):1712-1721. 10.1158/0008-5472.CAN-03-2700, 14996731.
23. Sanz L, Cuesta AM, Salas C, Corbacho C, Bellas C, Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest 2009, 89(1):91-97. 10.1038/labinvest.2008.108, 19002108.
24. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?. Eur J Cardiothorac Surg 2009, 36(3):454-459. 10.1016/j.ejcts.2009.03.054, 19502076.
25. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009, 85(2):217-221. 10.1038/clpt.2008.200, 19005462.
26. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn M. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 1993, 143(2):528-537. 1887031, 8342600.
27. Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, Obata Y, Stockert E, Hall CM, Old LJ. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther 2003, 2(8):729-737.
28. Demarchez M, Hartmann DJ, Prunieras M. An immunohistological study of the revascularization process in human skin transplanted onto the nude mouse. Transplantation 1987, 43(6):896-903.
29. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96(4):1815-1822. 10.1172/JCI118227, 185818, 7560073.
30. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001, 61(21):7846-7854.
31. Nemeth JA, Roberts JW, Mullins CM, Cher ML. Persistence of human vascular endothelium in experimental human prostate cancer bone tumors. Clin Exp Metastasis 2000, 18(3):231-237. 10.1023/A:1006752903175, 11315096.
32. Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 2012, 7(1):e29623. 10.1371/journal.pone.0029623, 3269421, 22303438.